Kotak Mutual Fund increased its stake in Biocon Limited from 1.29% to 2.57%, acquiring 2,09,66,435 shares to bring its total holding to 4,19,58,298 shares.
A leading biotechnology company engaged in the manufacture of innovative pharmaceutical products and research services across multiple therapeutic areas. Biocon specializes in biologics, biosimilars, and small molecule drugs, serving patients in oncology, immunology, and diabetes therapeutics globally. The company operates integrated manufacturing facilities and maintains a strong commitment to developing affordable healthcare solutions for patients in emerging markets worldwide.
Wholly owned subsidiary of Kotak Mahindra Bank, one of India's leading private banks. Manages over Rs 4.5 lakh crore in AUM. MD Nilesh Shah is a fixture in Indian financial media and one of the most quoted fund managers in the country. Known for disciplined quality growth positioning and clear communication of investment rationale to investors.
